NYMX: Nymox Pharmaceutical Corporation Instablogs

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 15, 4:39 PM Nymox (NYMX): Q1 EPS of -$0.03 beats by $0.02. Revenue of $184.2K misses by $595.8K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 15, 12:54 PM Nymox Pharmaceutical (NYMX +3%) gains on an upbeat Q1 report, halving its losses and more than doubling revenue Y/Y. The drug-maker posted a $0.03 per share net loss, down from a $0.06 per share loss during the same quarter last year and beating analyst forecasts for a loss of $0.05. Revenue surged 116% to $184K, which also easily topped expectations by over $105K, largely due to licensing agreements and an increase in orders from one customer for NicAlert/TobacAlert. Comment! [Healthcare, On the Move, Earnings]
Friday, May 3, 1:56 PM Nymox Pharmaceutical (NYMX +5%) jumps after completing enrollment in a final, pivotal Phase III trial for its benign prostatic hyperplasia treatment NX-1207. Previous results suggest the drug may be able to double average symptomatic improvements compared to conventional treatments. (I, II, III) Comment! [Healthcare, On the Move]
Tuesday, April 16, 3:41 PM Nymox Pharmaceutical (NYMX -0.8%) gives back gains made earlier in the day as the market shrugs off its announcement of positive data on NX-1207, its treatment for benign prostatic hyperplasia. The company says the drug has no detectable effect on sexual function in test subjects. Other drugs that are currently used to treat prostate ailments frequently cause collateral damage to sexual organs. 1 Comment [Healthcare, On the Move]
Monday, March 18, 4:03 PM Shares of Nymox Pharmaceutical (NYMX +25.2%) soar today, going out at their highs as the company says it will present data on NX-1207 at the European Association of Urology's annual meeting held in Milan, Italy. NX-1207 is in late stage Phase 3 development in the U.S. for the treatment of BPH, a common condition of older men associated with growth in prostate size as men age. 1 Comment [Healthcare, On the Move]
Monday, March 18, 12:48 PM Midday top 10 gainers: YRCW +25%. PRWT +22%. ULTR +17%. IG +17%. CHYR +16%. ATOS +14%. TA +13%. NYMX +13%. WILC +11%. SORL +11%.
Midday top 10 losers: AMBO -19%. PTX -12%. SOL -10%. CNET -10%. EMITF -9%. TSEM -8%. MNDO -8%. RGDX -8%. JVA -8%. AMBA -8%. 1 Comment [On the Move]
Tuesday, March 5, 4:01 PM Nymox Pharmaceutical (NYMX +3.2%) is set to close in the green today after the company provided a positive update on Phase 2 clinical trials for NX-1207, a drug being tested for early-stage prostate cancer. The trial has reached the halfway point in patient recruitment and safety assessments to date have shown no serious or unexpected adverse effects. The drug is also in Phase 3 clinical trials for treating benign prostatic hyperplasia and has been tested in 10 trials to date, of which 6 are ongoing or nearing completion. Comment! [Healthcare, On the Move]
Tuesday, February 19, 1:32 PM Nymox Pharmaceutical (NYMX +0.6%) ticks up after saying that Phase 3 immunogenicity trials of its lead drug candidate NX-1207 have not shown any evidence of eliciting an immune reaction in men treated with intraprostatic injections of the drug. Comment! [Healthcare]
Wednesday, November 28, 2012, 11:37 AM Nymox Pharmaceutical (NYMX +3.4%) says it's completed the patient enrollment process for its Phase III trial of NX-1207 for BPH. Top-line results are expected in late 2013, and include pivotal studies in the U.S. and Europe, re-injection studies in the U.S., prostate cancer trials, as well as other clinical and non-clinical research activities. Comment! [Healthcare, On the Move]
Thursday, October 25, 2012, 12:45 PM Midday top 10 gainers: PSSI +33%. PRLB +20%. CHTP +20%. NYMX +17%. TEN +16%. SPRT +15%. DDD +15%. OSTK +14%. VRS +13%. LOGM +13%.
Top 10 Losers: SPR -31%. BBW -25%. DEXO -23%. PACR -20%. CROX -19%. TBI -17%. LOGI -16%. DFT -15%. NYT -14%. SQNS -13%. Comment! [On the Move]
Tuesday, February 7, 2012, 11:14 AM The Obama administration plans to push for a $156M increase in funding for Alzheimer's research over the next two years after estimates for Alzheimer care in the U.S. range as high as $20T for the next 40 years with baby boomers squarely in harm's way. So far drug firms have only been able to deliver stopgap measures - instead of a cure - but big names NVS, JNJ, PFE, FRX are working on developing a market-changing home run treatment, as well as smaller-cap players such as AVXL, PRANA, AEN, NYMX, and ILNS. 2 Comments [Quick Ideas, Healthcare]
Friday, June 24, 2011, 4:29 PM Shares of Nymox Pharmaceutical (NYMX) surge higher on unusual volume in the final minutes to finish +17.9% on no apparent news. Comment! [On the Move, Healthcare]

NYMX Nymox Pharmaceutical Corporation

NYMX

Nymox Pharmaceutical Corporation